InfuSystem vs Neuronetics
INFU and STIM side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INFU and STIM compare
InfuSystem is the larger company, worth 2.8 times as much as Neuronetics ($293M against $106M).
Neuronetics grew revenue faster over the last twelve months (23.0% versus 2.4% for InfuSystem).
InfuSystem keeps more of each dollar of sales as profit, with a net margin of 6.5% compared with −14.4% at Neuronetics.
InfuSystem scores higher on the StockData Score (15 against 5 for Neuronetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INFU | STIM |
|---|---|---|
| Size and price | ||
| Market cap | $293M | $106M |
| Share price | $14.72 | $1.39 |
| Change, 1 year | 41.1% | −35.6% |
| Change, 5 years | −17.6% | −65.3% |
| Beta (5Y) | 1.18 | 1.59 |
| Employees | 473 | 658 |
| StockData Score | ||
| Total score | 15 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 32.7× | – |
| P/S | 2.0× | 0.7× (better) |
| P/B | 4.6× (better) | 5.7× |
| EV/EBITDA | 11.2× | – |
| P/FCF | 11.8× | – |
| FCF yield | 8.4% (better) | −9.1% |
| Fair value | $15.28 | – |
| Margin of safety | 3.7% | – |
| Growth | ||
| Revenue growth (TTM) | 2.4% | 23.0% (better) |
| Revenue growth, 5Y average | 8.1% | 24.8% (better) |
| Net income growth (TTM) | 70.9% | – |
| EPS growth (TTM) | 73.1% | – |
| EPS growth, 5Y average | −17.3% | – |
| Profitability | ||
| Gross margin | 57.6% (better) | 50.7% |
| Operating margin | 9.8% (better) | −9.4% |
| Net margin | 6.5% (better) | −14.4% |
| FCF margin | 17.1% (better) | −6.0% |
| Return on equity | 15.8% (better) | −100% |
| Return on invested capital | 13.4% (better) | −19.2% |
| Financial health | ||
| Debt / equity | 0.31 (better) | 3.30 |
| Net debt / EBITDA | 0.39 | – |
| Interest coverage | 13.8× (better) | −1.7× |
| Current ratio | 2.68 (better) | 2.01 |
| Altman Z-score | 5.75 (better) | −3.38 |
| Piotroski F-score | 8 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 2.1% | – |
| Shareholder yield | 2.1% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 79.1% | 48.8% |
| Held by insiders | 12.2% | 51.3% |
| Insider net buying, 12 months | $150K | $4.6M (better) |
| Short interest, % of float | 3.9% | 18.0% |
Go deeper
- INFU stock overview
- INFU income statement
- INFU valuation and score
- STIM stock overview
- STIM income statement
- STIM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.